Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond.
adoptive T-cell therapies
immune checkpoint blockade
immunotherapy
soft tissue sarcomas
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Mar 2023
07 Mar 2023
Historique:
received:
30
01
2023
revised:
03
03
2023
accepted:
05
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Sarcomas gather a heterogeneous group of mesenchymal malignant tumors including more than 150 different subtypes. Most of them represent aggressive tumors with poor prognosis at the advanced stage, despite the better molecular characterization of these tumors and the development of molecular-driven therapeutic strategies. During the last decade, immunotherapy has been developed to treat advanced cancers, mainly thanks to immune checkpoint inhibitors (ICI) such as anti-PD1/PDL1 and later to adoptive immune cell therapies. In this review, we aim to summarize the state of the art of immunotherapy in soft tissue sarcomas (STS). Overall, the clinical trials of ICI that included a wide diversity of STS subtypes reported limited efficacy with some outlying responders. Both emerging biomarkers are of interest in selecting good candidates and in the development of combination therapies. Finally, the recent breakthroughs of innovative adoptive therapies in STS seem highly promising.
Identifiants
pubmed: 36980528
pii: cancers15061643
doi: 10.3390/cancers15061643
pmc: PMC10046205
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Immunol Res. 2022 Apr;70(2):256-268
pubmed: 35043369
J Immunother Cancer. 2019 Aug 8;7(1):213
pubmed: 31395100
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
Cancer Immunol Res. 2019 Aug;7(8):1237-1243
pubmed: 31171504
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Cancer Res. 2012 Apr 1;72(7):1642-50
pubmed: 22311675
Clin Cancer Res. 2021 Dec 1;27(23):6424-6431
pubmed: 34475102
Front Immunol. 2021 Aug 20;12:705361
pubmed: 34489957
PLoS One. 2021 Feb 25;16(2):e0246958
pubmed: 33630918
Nat Immunol. 2006 Oct;7(10):1082-91
pubmed: 16936731
Curr Opin Oncol. 2020 Jul;32(4):295-300
pubmed: 32541316
Nat Rev Clin Oncol. 2020 Dec;17(12):725-741
pubmed: 32760014
Sarcoma. 2013;2013:168145
pubmed: 23554566
JAMA. 2020 Apr 7;323(13):1266-1276
pubmed: 32259228
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
Lancet Oncol. 2019 Jun;20(6):837-848
pubmed: 31078463
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34380663
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
J Immunol Methods. 1987 Aug 24;102(1):127-41
pubmed: 3305708
J Hematol Oncol. 2020 May 19;13(1):55
pubmed: 32430039
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Pharmacol Res. 2014 Jan;79:34-74
pubmed: 24269963
Medicine (Baltimore). 2018 Jun;97(25):e11004
pubmed: 29923984
Biomedicines. 2022 Feb 28;10(3):
pubmed: 35327375
Front Immunol. 2019 Oct 11;10:2250
pubmed: 31681259
Front Oncol. 2022 Mar 03;12:809068
pubmed: 35311098
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33203665
N Engl J Med. 2022 Jul 21;387(3):217-226
pubmed: 35857659
Cancer Treat Rev. 2020 Dec;91:102115
pubmed: 33130422
BMC Cancer. 2020 Jun 29;20(1):606
pubmed: 32600281
Oncol Lett. 2019 Apr;17(4):3937-3943
pubmed: 30881511
Cell. 2017 Nov 2;171(4):950-965.e28
pubmed: 29100075
Curr Oncol. 2022 Mar 02;29(3):1559-1574
pubmed: 35323331
Cancer Res. 1996 Nov 15;56(22):5150-5
pubmed: 8912850
J Hematol Oncol. 2020 Jul 2;13(1):86
pubmed: 32616000
Nat Med. 2022 Jun;28(6):1199-1206
pubmed: 35618839
J Natl Cancer Inst. 2013 Feb 20;105(4):256-65
pubmed: 23291374
Ann Surg Oncol. 2023 Feb;30(2):683-685
pubmed: 36396869
CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109
pubmed: 15061599
Cancer J. 2015 Nov-Dec;21(6):506-9
pubmed: 26588684
Nat Med. 2020 Feb;26(2):181-187
pubmed: 32042194
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
Iowa Orthop J. 2006;26:154-8
pubmed: 16789469
J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66
pubmed: 8028037
J Immunother. 2021 Feb-Mar 01;44(2):63-70
pubmed: 33443972
Clin Cancer Res. 2020 Mar 15;26(6):1258-1266
pubmed: 31900276
Nat Commun. 2022 Jun 15;13(1):3405
pubmed: 35705560
Clin Cancer Res. 2013 Sep 1;19(17):4792-800
pubmed: 23690483
Cell. 2017 Nov 16;171(5):1042-1056.e10
pubmed: 29056344
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Lancet Oncol. 2021 Jan;22(1):51-65
pubmed: 33285097
Ann Oncol. 2021 Nov;32(11):1348-1365
pubmed: 34303806
Clin Cancer Res. 2007 Dec 15;13(24):7314-21
pubmed: 18094412
J Clin Oncol. 2015 May 20;33(15):1688-96
pubmed: 25800760
JAMA Oncol. 2020 Nov 01;6(11):1778-1782
pubmed: 32910151
Ecancermedicalscience. 2020 Dec 03;14:1150
pubmed: 33574895
Cancer. 2021 Aug 15;127(16):2934-2942
pubmed: 33910263
J Thorac Oncol. 2021 May;16(5):860-867
pubmed: 33476803
J Immunother Cancer. 2017 Jul 18;5(1):58
pubmed: 28716069
JAMA Oncol. 2018 Jan 01;4(1):93-97
pubmed: 28662235
Clin Cancer Res. 2020 Dec 15;26(24):6445-6452
pubmed: 33046518
J Immunol. 2005 Jun 15;174(12):7516-23
pubmed: 15944250
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336